Amgen and Rosa present a model of B-precursor acute lymphoblastic leukemia at ASCPT 2014

Amgen and Rosa presented a poster, entitled "Pharmacology Model to Characterize the Effect of Blinatumomab in Patients With Adult B-Precursor Acute Lymphoblastic Leukemia" at the American Society of Clinical Phamacology and Therapeutics Conference in Atlanta, GA on March 18 (Biologics pre-conference) and 21, 2014. The poster describes key questions addressed with a quantitative systems pharmacology model (PhysioPD™ Model) that represents the pathophysiology of B-Precursor Acute Lymphoblastic Leukemia and the effect of blinatumomab, a T-cell activator that leads to B-cell death.